MERIDEN, Conn., Aug. 10, 2016 /PRNewswire/ -- Protein Sciences Corporation announced that the FDA has approved and released the first lots of Flublok® influenza vaccine for distribution this season. Doses have been shipped and healthcare professionals and pharmacies that have pre-ordered Flublok should receive the vaccine this week. The Company also announced the launch of their brand new Flublok Finder that is incorporated into the Flublok website, enabling consumers to find the nearest Flublok location with ease. To find your nearest Flublok vaccination center, input your zip code at https://www.flublok.com/get-flublok/flublok-finder/
Flublok is approved for all people 18 and older and was recently shown in a clinical study of adults 50 and older to provide over 40% better protection against cell culture confirmed influenza compared to a flu vaccine made using embryonated hens' eggs the 60 – year old vaccine production technology. Flublok also offers a pure choice for vaccination as it is comprised of purified protein and lacks the unnecessary ingredients contained in other flu vaccines, such as influenza virus, antibiotics, preservatives, egg protein, gelatin or latex.
"With early release of Flublok, we will be one of the first vaccines available to protect adults," said Manon Cox, President and CEO of Protein Sciences Corporation. "You have a choice in flu vaccines and why not demand the vaccine made with today's technology Flublok."
For more information about Flublok, please visit www.flublok.com.
About Protein Sciences
Protein Sciences specializes in vaccine development and protein production. Our mission is our inspiration: to save lives and improve health through the creation of innovative vaccines and biopharmaceuticals.
Flublok, the world's first recombinant protein-based vaccine for the prevention of seasonal influenza disease, was initially approved by the U.S. FDA in January 2013. FDA expanded its approval in October 2014 to include everyone over 18 years and approved a nine month shelf life in June 2016. Flublok is also licensed for sale in Mexico and licensure in additional countries, including Japan, is expected in the near future. Flublok is the only flu vaccine made in a 100% egg-free system using modern cell culture technology, making it unnecessary to use an infectious influenza virus, antibiotics or harsh chemicals in manufacturing. Flublok is highly purified and does not contain any preservatives (e.g., thimerosal, which contains mercury), egg proteins, gelatin or latex. In addition, Flublok contains three times more antigen than traditional flu vaccines (3x45mcg hemagglutinin protein versus 3x15mcg hemagglutinin protein) and was shown to have superior efficacy in a 2014/15 post-marketing study.* Flublok is an accurate copy of the virus coat and is not subject to the egg-adapted mutations associated with low vaccine effectiveness (see Skowronski et al. (2014) PLOS ONE 9(3), e92153).
Healthcare professionals wishing to order Flublok should contact one of the following distributors:
- Protein Sciences Corporation: 203-686-0800
- FFF Enterprises: 800-843-7477 www.myfluvaccine.com
- Cardinal Health: 866-677-4844 http://www.cardinal.com/us/en/SPD/Ordering
- McKesson: 877-MCK-4FLU mms.mckesson.com
- Moore Medical: 800-234-1464 www.mooremedical.com/flu
- Henry Schein: 1-800-772-4346 www.henryschein.com
Flublok Safety Information
Flublok is approved for people 18 and older to prevent influenza disease. The most common side effect from Flublok is pain at the site of injection. Headache, fatigue or muscle ache may occur.
Tell the doctor if you have ever experienced Guillain-Barré syndrome (severe muscle weakness) or have had a severe allergic reaction to any component of Flublok vaccine.
Vaccination with Flublok may not protect all individuals. Clinical effectiveness in adults 50 and older is based on the immune response elicited by Flublok and not on demonstration of decreased influenza disease.
*Flublok demonstrated a higher antibody response to the A strains in two field trials in adults >50 years old. The B strain antibody responses were comparable to traditional trivalent and quadrivalent vaccines.
SOURCE Protein Sciences Corporation